Astrazeneca Entered Into An Exclusive License Agreement With CSPC Pharmaceutical Group To Advance The Development Of An Early Stage, Novel Small Molecule Lipoprotein (A) (LP(A)) Disruptor
Astrazeneca Entered Into An Exclusive License Agreement With CSPC Pharmaceutical Group To Advance The Development Of An Early Stage, Novel Small Molecule Lipoprotein (A) (LP(A)) Disruptor
AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This asset further strengthens the company's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease.
阿斯利康已与CSPC药品集团有限公司(CSPC)签订独家许可协议，推进早期小分子脂蛋白(a)(Lp(a))破坏剂的开发，该药物有潜力为患有血脂异常的患者提供额外好处。这一资产进一步强化了公司的心血管产品组合，有助于应对主要驱动慢性心血管疾病的主要风险因素。
Under the terms of the agreement, AstraZeneca will receive access to CSPC's pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with the oral small molecule PCSK9 inhibitor, AZD0780.
根据协议条款，阿斯利康将获得CSPC的临床前候选小分子YS2302018，一种口服Lp(a)破坏剂，旨在将其开发为一种新型降脂疗法，在心血管疾病领域以及单独或与口服小分子PCSK9抑制剂AZD0780组合的多种心血管疾病适应症中发挥潜力。
